HPV Associated Disorders Treatment Market - Top Companies and Manufacturers

Companies Dominating the HPV Associated Disorders Treatment Landscape

Companies dominating this market are adopting a wide number of strategies for market expansion and to gain a competitive edge. Few companies such as Merck and GlaxoSmithKline leverage the market with extensive marketing and education campaigns for their vaccines. Similarly, companies also adopt strategies such as partnerships for R&D, mergers, acquisitions, and launches. For instance, in December 2022, Moderna, Inc. and Merck announced the successful trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA. Additionally, emerging biotech firms are exploring personalized medicine approaches, emphasizing tailored therapies, and diversifying treatment options, and driving HPV associated disorders treatment market growth. Some of the key market players include:

Biocon Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Bristol-Myers Squibb Company
Cleveland Clinic
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Hologic, Inc.
INOVIO Pharmaceuticals
Johnson & Johnson Services Inc. (Janssen Pharmaceutical)
Mayo Foundation for Medical Education and Research (MFMER).
Memorial Sloan Kettering Cancer Center
The Johns Hopkins Hospital

Browse Key Market Insights with Data Illustration:

HPV Associated Disorders Treatment Market Size Report 2037

In the News

In March 2024, Merck, Inc. announced the clinical development of a new investigational multi-valent HPV vaccine, intended to offer broader protection against multiple HPV types
In February 2023, Hologic received U.S. FDA approval for its new Genius Digital Diagnostics System with the Genius Cervical AI algorithm. It first and only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify cervical cancers
In June 2022, Roche AG announced the launch of human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. The screening is aimed at helping women identify the risk of developing cervical cancer and treat it early before it has a chance to develop

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the HPV associated disorders treatment market was over USD 20.7 billion.

The market size for the HPV associated disorders treatment market is projected to reach USD 35.5 billion by the end of 2037 expanding at a CAGR of 4.6% during the forecast period i.e., between 2025-2037.

The major players in the market are Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Hologic, Inc., INOVIO Pharmaceuticals, and others.

In terms of end use segment, the hospitals segment is anticipated to garner the largest market share of 45.1% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 47.0% by the end of 2037 and provide more business opportunities in the future.

HPV Associated Disorders Treatment Market - Top Companies and Manufacturers

Companies Dominating the HPV Associated Disorders Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the HPV associated disorders treatment market?

What is the outlook for the HPV associated disorders treatment market?

Who are the major players dominating the HPV associated disorders treatment market?

Which end use segment will capture the significant market share for the HPV associated disorders treatment market by 2037?

Which region will provide more business opportunities for the growth of the HPV associated disorders treatment market in the future?